Human Respiratory Syncytial Virus: Infection and Pathology

Abstract

The human respiratory syncytial virus (hRSV) is by far the major cause of acute lower respiratory tract infections (ALRTIs) worldwide in infants and children younger than 2 years. The overwhelming number of hospitalizations due to hRSV-induced ALRTI each year is due, at least in part, to the lack of licensed vaccines against this virus. Thus, hRSV infection is considered a major public health problem and economic burden in most countries. The lung pathology developed in hRSV-infected individuals is characterized by an exacerbated proinflammatory and unbalanced Th2-type immune response. In addition to the adverse effects in airway tissues, hRSV infection can also cause neurologic manifestations in the host, such as seizures and encephalopathy. Although the origins of these extrapulmonary symptoms remain unclear, studies with patients suffering from neurological alterations suggest an involvement of the inflammatory response against hRSV. Furthermore, hRSV has evolved numerous mechanisms to modulate and evade the immune response in the host. Several studies have focused on elucidating the interactions between hRSV virulence factors and the host immune system, to rationally design new vaccines and therapies against this virus. Here, we discuss about the infection, pathology, and immune response triggered by hRSV in the host.

Keywords

human respiratory syncytial virus - virulence factors - innate immune response - adaptive immune response - extrapulmonary manifestations - central nervous system

• References

• 1 Calvo C, García-García ML, Blanco C , et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. J Clin Virol 2008; 42 (3) 268-272
• 2 Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004; 5 (Suppl A): S119-S126
• 3 González PA, Prado CE, Leiva ED , et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci U S A 2008; 105 (39) 14999-15004
• 4 Bueno SM, González PA, Pacheco R , et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008; 8 (10) 1320-1329
• 5 Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162 (1–2) 80-99
• 6 Sweetman LL, Ng YT, Butler IJ, Bodensteiner JB. Neurologic complications associated with respiratory syncytial virus. Pediatr Neurol 2005; 32 (5) 307-310
• 7 Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137 (6) 865-870
• 8 Wang EE, Law BJ, Boucher FD , et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996; 129 (3) 390-395
• 9 Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002; 96 (Suppl B ): S9-S14
• 10 Navas L, Wang E, de Carvalho V, Robinson J ; Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992; 121 (3) 348-354
• 11 Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82 (5) 2040-2055
• 12 Nair H, Nokes DJ, Gessner BD , et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375 (9725) 1545-1555
• 13 Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22 (5) 275-284
• 14 Halfhide CP, Flanagan BF, Brearey SP , et al. Respiratory syncytial virus binds and undergoes transcription in neutrophils from the blood and airways of infants with severe bronchiolitis. J Infect Dis 2011; 204 (3) 451-458
• 15 Hall CB, Douglas Jr RG, Schnabel KC, Geiman JM. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981; 33 (3) 779-783
• 16 Storey S. Respiratory syncytial virus market. Nat Rev Drug Discov 2010; 9 (1) 15-16
• 17 Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998; 11 (3) 430-439
• 18 van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012; 2 (3) 300-305
• 19 González PA, Bueno SM, Riedel CA, Kalergis AM. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009; 16 (34) 4609-4625
• 20 Bont L, Versteegh J, Swelsen WT , et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002; 52 (3) 363-367
• 21 Guo-Parke H, Canning P, Douglas I , et al. Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium. Am J Respir Crit Care Med 2013; 188 (7) 842-851
• 22 Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol 2015; 235 (2) 266-276
• 23 Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL. Respiratory syncytial virus: current progress in vaccine development. Viruses 2013; 5 (2) 577-594
• 24 Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol 2013; 2013: 359683
• 25 Lanari M, Silvestri M, Rossi GA. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants. Curr Drug Metab 2013; 14 (2) 216-225
• 26 Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection—a systematic review. Crit Care 2006; 10 (4) R107
• 27 Esposito S, Salice P, Bosis S , et al. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection. BMC Infect Dis 2010; 10: 305
• 28 Kirin BK, Topić RZ, Dodig S. Hepatitis during respiratory syncytial virus infection—a case report. Biochem Med (Zagreb) 2013; 23 (1) 112-116
• 29 Hacking D, Hull J. Respiratory syncytial virus—viral biology and the host response. J Infect 2002; 45 (1) 18-24
• 30 Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66 (3) 281-290
• 31 Collins P, Chanock R, Murphy B. Respiratory Syncytial Virus. Philadelphia, PA: Lippincott Williams & Wilkins; 2001
• 32 Lay MK, González PA, León MA , et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 2013; 15 (3) 230-242
• 33 McLellan JS, Chen M, Joyce MG , et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342 (6158) 592-598
• 34 Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy—a review. Virus Genes 2006; 33 (2) 235-252
• 35 Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 2007; 25 (41) 7271-7279
• 36 Mastrangelo P, Hegele RG. RSV fusion: time for a new model. Viruses 2013; 5 (3) 873-885
• 37 Marr N, Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication. Innate Immun 2012; 18 (6) 856-865
• 38 Behera AK, Matsuse H, Kumar M, Kong X, Lockey RF, Mohapatra SS. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun 2001; 280 (1) 188-195
• 39 Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 2011; 17 (9) 1132-1135
• 40 Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005; 18 (3) 541-555
• 41 Krusat T, Streckert HJ. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 1997; 142 (6) 1247-1254
• 42 Malhotra R, Ward M, Bright H , et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 2003; 5 (2) 123-133
• 43 Bukreyev A, Yang L, Fricke J , et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 2008; 82 (24) 12191-12204
• 44 Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 2006; 176 (3) 1600-1608
• 45 Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2 (8) 732-738
• 46 Langedijk JP, de Groot BL, Berendsen HJ, van Oirschot JT. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 1998; 243 (2) 293-302
• 47 Rixon HW, Brown G, Aitken J, McDonald T, Graham S, Sugrue RJ. The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection. J Gen Virol 2004; 85 (Pt 5) 1153-1165
• 48 Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of the respiratory syncytial virus small hydrophobic protein. J Virol 2007; 81 (15) 8361-8366
• 49 Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 2008; 17 (5) 813-820
• 50 Triantafilou K, Kar S, Vakakis E, Kotecha S, Triantafilou M. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax 2013; 68 (1) 66-75
• 51 Gan SW, Tan E, Lin X , et al. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem 2012; 287 (29) 24671-24689
• 52 Ruigrok RW, Crépin T. Nucleoproteins of negative strand RNA viruses; RNA binding, oligomerisation and binding to polymerase co-factor. Viruses 2010; 2 (1) 27-32
• 53 Tawar RG, Duquerroy S, Vonrhein C , et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 2009; 326 (5957) 1279-1283
• 54 Le Mercier P, Garcin D, Hausmann S, Kolakofsky D. Ambisense sendai viruses are inherently unstable but are useful to study viral RNA synthesis. J Virol 2002; 76 (11) 5492-5502
• 55 El Omari K, Dhaliwal B, Ren J , et al. Structures of respiratory syncytial virus nucleocapsid protein from two crystal forms: details of potential packing interactions in the native helical form. Acta Crystallogr Sect F Struct Biol Cryst Commun 2011; 67 (Pt 10) 1179-1183
• 56 Hanna S, Tibby SM, Durward A, Murdoch IA. Incidence of hyponatraemia and hyponatraemic seizures in severe respiratory syncytial virus bronchiolitis. Acta Paediatr 2003; 92 (4) 430-434
• 57 Lifland AW, Jung J, Alonas E, Zurla C, Crowe Jr JE, Santangelo PJ. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. J Virol 2012; 86 (15) 8245-8258
• 58 Céspedes PF, Bueno SM, Ramírez BA , et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci USA 2014; 111 (31) E3214-E3223
• 59 Cowton VM, McGivern DR, Fearns R. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 2006; 87 (Pt 7) 1805-1821
• 60 Slack MS, Easton AJ. Characterization of the interaction of the human respiratory syncytial virus phosphoprotein and nucleocapsid protein using the two-hybrid system. Virus Res 1998; 55 (2) 167-176
• 61 Tran TL, Castagné N, Bhella D , et al. The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol 2007; 88 (Pt 1): 196-206
• 62 Sourimant J, Rameix-Welti MA, Gaillard AL , et al. Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein. J Virol 2015; 89 (8) 4421-4433
• 63 Lu B, Ma CH, Brazas R, Jin H. The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. J Virol 2002; 76 (21) 10776-10784
• 64 Grosfeld H, Hill MG, Collins PL. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol 1995; 69 (9) 5677-5686
• 65 Fearns R, Collins PL, Peeples ME. Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus. J Virol 2000; 74 (13) 6006-6014
• 66 Hardy RW, Wertz GW. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol 1998; 72 (1) 520-526
• 67 Kuo L, Fearns R, Collins PL. The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome. J Virol 1996; 70 (9) 6143-6150
• 68 Teng MN, Collins PL. Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol 1998; 72 (7) 5707-5716
• 69 Ghildyal R, Baulch-Brown C, Mills J, Meanger J. The matrix protein of Human respiratory syncytial virus localises to the nucleus of infected cells and inhibits transcription. Arch Virol 2003; 148 (7) 1419-1429
• 70 Ghildyal R, Ho A, Wagstaff KM , et al. Nuclear import of the respiratory syncytial virus matrix protein is mediated by importin beta1 independent of importin alpha. Biochemistry 2005; 44 (38) 12887-12895
• 71 Ghildyal R, Ho A, Dias M , et al. The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism. J Virol 2009; 83 (11) 5353-5362
• 72 Bian T, Gibbs JD, Örvell C, Imani F. Respiratory syncytial virus matrix protein induces lung epithelial cell cycle arrest through a p53 dependent pathway. PLoS ONE 2012; 7 (5) e38052
• 73 Mitra R, Baviskar P, Duncan-Decocq RR, Patel D, Oomens AG. The human respiratory syncytial virus matrix protein is required for maturation of viral filaments. J Virol 2012; 86 (8) 4432-4443
• 74 Li D, Jans DA, Bardin PG, Meanger J, Mills J, Ghildyal R. Association of respiratory syncytial virus M protein with viral nucleocapsids is mediated by the M2-1 protein. J Virol 2008; 82 (17) 8863-8870
• 75 Ghildyal R, Mills J, Murray M, Vardaxis N, Meanger J. Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. J Gen Virol 2002; 83 (Pt 4) 753-757
• 76 Ghildyal R, Li D, Peroulis I , et al. Interaction between the respiratory syncytial virus G glycoprotein cytoplasmic domain and the matrix protein. J Gen Virol 2005; 86 (Pt 7) 1879-1884
• 77 Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol 1999; 73 (7) 5852-5864
• 78 Tran TL, Castagné N, Dubosclard V , et al. The respiratory syncytial virus M2-1 protein forms tetramers and interacts with RNA and P in a competitive manner. J Virol 2009; 83 (13) 6363-6374
• 79 Kiss G, Holl JM, Williams GM , et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J Virol 2014; 88 (13) 7602-7617
• 80 Cartee TL, Wertz GW. Respiratory syncytial virus M2-1 protein requires phosphorylation for efficient function and binds viral RNA during infection. J Virol 2001; 75 (24) 12188-12197
• 81 Mason SW, Aberg E, Lawetz C, DeLong R, Whitehead P, Liuzzi M. Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity. J Virol 2003; 77 (19) 10670-10676
• 82 Reimers K, Buchholz K, Werchau H. Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B. Virology 2005; 331 (2) 260-268
• 83 Cheng X, Park H, Zhou H, Jin H. Overexpression of the M2-2 protein of respiratory syncytial virus inhibits viral replication. J Virol 2005; 79 (22) 13943-13952
• 84 Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A 1999; 96 (20) 11259-11264
• 85 Munir S, Hillyer P, Le Nouën C , et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog 2011; 7 (4) e1001336
• 86 Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol 2008; 82 (17) 8780-8796
• 87 Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 2005; 79 (9) 5353-5362
• 88 Wright PF, Karron RA, Madhi SA , et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006; 193 (4) 573-581
• 89 Elliott J, Lynch OT, Suessmuth Y , et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol 2007; 81 (7) 3428-3436
• 90 Wu W, Tran KC, Teng MN , et al. The interactome of the human respiratory syncytial virus NS1 protein highlights multiple effects on host cell biology. J Virol 2012; 86 (15) 7777-7789
• 91 Qin L, Peng D, Hu C , et al. Differentiation of Th subsets inhibited by nonstructural proteins of respiratory syncytial virus is mediated by ubiquitination. PLoS ONE 2014; 9 (7) e101469
• 92 Lambert DM. Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins. Virology 1988; 164 (2) 458-466
• 93 San-Juan-Vergara H, Sampayo-Escobar V, Reyes N , et al. Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells. J Virol 2012; 86 (3) 1832-1843
• 94 Asenjo A, Rodríguez L, Villanueva N. Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: a possible role for serine 54. J Gen Virol 2005; 86 (Pt 4) 1109-1120
• 95 Carromeu C, Simabuco FM, Tamura RE, Farinha Arcieri LE, Ventura AM. Intracellular localization of human respiratory syncytial virus L protein. Arch Virol 2007; 152 (12) 2259-2263
• 96 Burke E, Mahoney NM, Almo SC, Barik S. Profilin is required for optimal actin-dependent transcription of respiratory syncytial virus genome RNA. J Virol 2000; 74 (2) 669-675
• 97 Brown G, Rixon HW, Steel J , et al. Evidence for an association between heat shock protein 70 and the respiratory syncytial virus polymerase complex within lipid-raft membranes during virus infection. Virology 2005; 338 (1) 69-80
• 98 Munday DC, Wu W, Smith N , et al. Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis. J Virol 2015; 89 (2) 917-930
• 99 Mink MA, Stec DS, Collins PL. Nucleotide sequences of the 3′ leader and 5′ trailer regions of human respiratory syncytial virus genomic RNA. Virology 1991; 185 (2) 615-624
• 100 Rodriguez R, Ramilo O. Respiratory syncytial virus: how, why and what to do. J Infect 2014; 68 (Suppl. 01) S115-S118
• 101 Low KW, Tan T, Ng K, Tan BH, Sugrue RJ. The RSV F and G glycoproteins interact to form a complex on the surface of infected cells. Biochem Biophys Res Commun 2008; 366 (2) 308-313
• 102 Jumat MR, Yan Y, Ravi LI , et al. Morphogenesis of respiratory syncytial virus in human primary nasal ciliated epithelial cells occurs at surface membrane microdomains that are distinct from cilia. Virology 2015; 484: 395-411
• 103 Shaikh FY, Cox RG, Lifland AW , et al. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. MBio 2012; 3 (1) 270-271
• 104 Ravi LI, Liang L, Wong PS, Brown G, Tan BH, Sugrue RJ. Increased hydroxymethylglutaryl coenzyme A reductase activity during respiratory syncytial virus infection mediates actin dependent inter-cellular virus transmission. Antiviral Res 2013; 100 (1) 259-268
• 105 Utley TJ, Ducharme NA, Varthakavi V , et al. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2. Proc Natl Acad Sci U S A 2008; 105 (29) 10209-10214
• 106 Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970; 23 (1) 7-18
• 107 Zeng R, Cui Y, Hai Y, Liu Y. Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines. Virus Res 2012; 167 (2) 138-145
• 108 Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006; 176 (3) 1733-1740
• 109 Lukacs NW, Smit JJ, Mukherjee S, Morris SB, Nunez G, Lindell DM. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. J Immunol 2010; 185 (4) 2231-2239
• 110 Murawski MR, Bowen GN, Cerny AM , et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83 (3) 1492-1500
• 111 Baum A, García-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 2010; 38 (5) 1283-1299
• 112 Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005; 79 (6) 3350-3357
• 113 Arnold R, König W. Respiratory syncytial virus infection of human lung endothelial cells enhances selectively intercellular adhesion molecule-1 expression. J Immunol 2005; 174 (11) 7359-7367
• 114 Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 1999; 163 (5) 2816-2820
• 115 Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23 (2) 327-333
• 116 LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 2001; 167 (10) 5868-5873
• 117 Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol 2001; 63: 521-554
• 118 Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77 (4) 931-962
• 119 Hickling TP, Bright H, Wing K , et al. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999; 29 (11) 3478-3484
• 120 Lee HC, Headley MB, Loo YM , et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012; 130 (5) 1187-1196.e5
• 121 Qiao J, Li A, Jin X. TSLP from RSV-stimulated rat airway epithelial cells activates myeloid dendritic cells. Immunol Cell Biol 2011; 89 (2) 231-238
• 122 Zeng S, Wu J, Liu J, Qi F, Liu B. IL-33 receptor (ST2) signalling is important for regulation of Th2-mediated airway inflammation in a murine model of acute respiratory syncytial virus infection. Scand J Immunol 2015; 81 (6) 494-501
• 123 Miazgowicz MM, Elliott MS, Debley JS, Ziegler SF. Respiratory syncytial virus induces functional thymic stromal lymphopoietin receptor in airway epithelial cells. J Inflamm Res 2013; 6: 53-61
• 124 Swedan S, Musiyenko A, Barik S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol 2009; 83 (19) 9682-9693
• 125 Lindemans CA, Coffer PJ, Schellens IM, de Graaff PM, Kimpen JL, Koenderman L. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. J Immunol 2006; 176 (9) 5529-5537
• 126 McDermott DS, Knudson CJ, Varga SM. Determining the breadth of the respiratory syncytial virus-specific T cell response. J Virol 2014; 88 (6) 3135-3143
• 127 Connors M, Kulkarni AB, Firestone CY , et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 1992; 66 (12) 7444-7451
• 128 Kruijsen D, Schijf MA, Lukens MV , et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 2011; 29 (15) 2730-2741
• 129 Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001; 15 (4) 637-646
• 130 Stoppelenburg AJ, de Roock S, Hennus MP, Bont L, Boes M. Elevated Th17 response in infants undergoing respiratory viral infection. Am J Pathol 2014; 184 (5) 1274-1279
• 131 Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection. J Immunol 2010; 185 (12) 7633-7645
• 132 Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, de Swart RL, Osterhaus AD. HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J Virol 2000; 74 (21) 10240-10244
• 133 Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol 2008; 82 (8) 4115-4124
• 134 Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997; 186 (3) 421-432
• 135 Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med 2002; 8 (1) 54-60
• 136 DiNapoli JM, Murphy BR, Collins PL, Bukreyev A. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virol J 2008; 5: 105
• 137 de Graaff PM, de Jong EC, van Capel TM , et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol 2005; 175 (9) 5904-5911
• 138 Bartz H, Türkel O, Hoffjan S, Rothoeft T, Gonschorek A, Schauer U. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells. Immunology 2003; 109 (1) 49-57
• 139 Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol 2000; 165 (1) 15-19
• 140 Carreño LJ, Riquelme EM, González PA , et al. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proc Natl Acad Sci U S A 2010; 107 (1) 210-215
• 141 Lee DC, Harker JA, Tregoning JS , et al. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010; 84 (17) 8790-8798
• 142 Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJ. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol 2013; 87 (20) 10946-10954
• 143 Reed M, Morris SH, Jang S, Mukherjee S, Yue Z, Lukacs NW. Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection. J Immunol 2013; 191 (5) 2526-2537
• 144 Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER stress-associated IL-1. Mucosal Immunol 2015; 8 (5) 1118-1130
• 145 Angel Rico M, Trento A, Ramos M , et al. Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes. Immunol Cell Biol 2009; 87 (4) 344-350
• 146 Torres JP, Gomez AM, Khokhar S , et al. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res 2010; 11: 125
• 147 Rivera-Toledo E, Gómez B. Respiratory syncytial virus persistence in macrophages alters the profile of cellular gene expression. Viruses 2012; 4 (12) 3270-3280
• 148 Li XQ, Fu ZF, Alvarez R, Henderson C, Tripp RA. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol 2006; 80 (1) 537-540
• 149 Tripp RA, Moore D, Barskey IV A , et al. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J Infect Dis 2002; 185 (10) 1388-1394
• 150 O'Donnell DR, McGarvey MJ, Tully JM, Balfour-Lynn IM, Openshaw PJ. Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. J Pediatr 1998; 133 (2) 272-274
• 151 Thorburn K, Hart CA. Think outside the box: extrapulmonary manifestations of severe respiratory syncytial virus infection. Crit Care 2006; 10 (4) 159
• 152 Eisenhut M, Sidaras D, Johnson R, Newland P, Thorburn K. Cardiac Troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease. Acta Paediatr 2004; 93 (7) 887-890
• 153 Thorburn K, Eisenhut M, Shauq A, Narayanswamy S, Burgess M. Right ventricular function in children with severe respiratory syncytial virus (RSV) bronchiolitis. Minerva Anestesiol 2011; 77 (1) 46-53
• 154 Checchia PA, Appel HJ, Kahn S , et al. Myocardial injury in children with respiratory syncytial virus infection. Pediatr Crit Care Med 2000; 1 (2) 146-150
• 155 Giles TD, Gohd RS. Respiratory syncytial virus and heart disease. A report of two cases. JAMA 1976; 236 (10) 1128-1130
• 156 Huang M, Bigos D, Levine M. Ventricular arrhythmia associated with respiratory syncytial viral infection. Pediatr Cardiol 1998; 19 (6) 498-500
• 157 Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980; 96 (2) 179-186
• 158 Dabbah H, Glikman D, Zonis Z. Pericardial effusion in an infant with severe respiratory syncytial virus bronchiolitis. Cardiol Young 2013; 23 (2) 299-300
• 159 Eisenhut M, Thorburn K, Ahmed T. Transaminase levels in ventilated children with respiratory syncytial virus bronchiolitis. Intensive Care Med 2004; 30 (5) 931-934
• 160 Nadal D, Wunderli W, Meurmann O, Briner J, Hirsig J. Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis 1990; 22 (1) 91-93
• 161 Wu J, Wang Z, Wang D. Respiratory virus expression in renal tissues and urine of children with steroid responsive simple nephrotic syndrome. [in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38: 969-972
• 162 Liu XM, Wang Z, Guo Y. Respiratory syncytial virus nephropathy in rats. Kidney Int 2007; 71 (5) 388-396
• 163 Morichi S, Kawashima H, Ioi H , et al. Classification of acute encephalopathy in respiratory syncytial virus infection. J Infect Chemother 2011; 17 (6) 776-781
• 164 Eisenhut M. Cerebral involvement in respiratory syncytial virus disease. Brain Dev 2007; 29 (7) 454
• 165 Millichap JJ, Wainwright MS. Neurological complications of respiratory syncytial virus infection: case series and review of literature. J Child Neurol 2009; 24 (12) 1499-1503
• 166 Miyamoto K, Fujisawa M, Hozumi H , et al. Systemic inflammatory response syndrome and prolonged hypoperfusion lesions in an infant with respiratory syncytial virus encephalopathy. J Infect Chemother 2013; 19 (5) 978-982
• 167 Kawashima H, Kashiwagi Y, Ioi H , et al. Production of chemokines in respiratory syncytial virus infection with central nervous system manifestations. J Infect Chemother 2012; 18 (6) 827-831
• 168 Kho N, Kerrigan JF, Tong T, Browne R, Knilans J. Respiratory syncytial virus infection and neurologic abnormalities: retrospective cohort study. J Child Neurol 2004; 19 (11) 859-864
• 169 Antonucci R, Fanos V. Acute encephalopathy associated with respiratory syncytial virus infections in childhood. A literature review. Minerva Pediatr 2005; 57 (3) 137-142
• 170 Otake Y, Yamagata T, Morimoto Y , et al. Elevated CSF IL-6 in a patient with respiratory syncytial virus encephalopathy. Brain Dev 2007; 29 (2) 117-120
• 171 Rayyan M, Naulaers G, Daniels H, Allegaert K, Debeer A, Devlieger H. Characteristics of respiratory syncytial virus-related apnoea in three infants. Acta Paediatr 2004; 93 (6) 847-849
• 172 Lindgren C, Grögaard J. Reflex apnoea response and inflammatory mediators in infants with respiratory tract infection. Acta Paediatr 1996; 85 (7) 798-803
• 173 Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. Respir Res 2002; 3 (Suppl. 01) S21-S25
• 174 Espinoza JA, Bohmwald K, Céspedes PF , et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci U S A 2013; 110 (22) 9112-9117
• 175 Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 2006; 1 (1) 122-124
• 176 Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1 (2) 848-858
• 177 Donnerstein RL, Berg RA, Shehab Z, Ovadia M. Complex atrial tachycardias and respiratory syncytial virus infections in infants. J Pediatr 1994; 125 (1) 23-28
• 178 Menchise A. Myocarditis in the setting of RSV bronchiolitis. Fetal Pediatr Pathol 2011; 30 (1) 64-68
• 179 Puchkov GF, Min'kovich BM. Respiratory syncytial infection in a child complicated by interstitial myocarditis with fatal outcome [in Russian]. Arkh Patol 1972; 34 (1) 70-73
• 180 Akins PT, Belko J, Uyeki TM, Axelrod Y, Lee KK, Silverthorn J. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care 2010; 13 (3) 396-406
• 181 Zlateva KT, Van Ranst M. Detection of subgroup B respiratory syncytial virus in the cerebrospinal fluid of a patient with respiratory syncytial virus pneumonia. Pediatr Infect Dis J 2004; 23 (11) 1065-1066